.Attributes Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin caused improved progression-free and general survival, causing FDA commendation and also a new therapy possibility for patients.